AMGEN INC. DL-,0001/ US0311621009 /
30/08/2024 08:04:15 | Chg. +4.50 | Volume | Bid16:04:55 | Ask16:04:55 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
298.90EUR | +1.53% | 0 Turnover: 0.00 |
302.15Bid Size: 750 | 302.45Ask Size: 750 | 162.34 bill.EUR | - | - |
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
27/06
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
27/06
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
25/06
Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025
GlobeNewswire
20/06
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...